Journal of the National Comprehensive Cancer Network

Papers
(The median citation count of Journal of the National Comprehensive Cancer Network is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Localized Gastroesophageal Cancers: Can We Shift the Current Treatment Paradigms?1232
CLO23-035: Expression of PD-L1 Through Evolution Phase From Pre-Invasive to Invasive Lung Adenocarcinoma1028
HSR23-103: Pancreatic Cancer: The Impact of Early Connectivity and Coordination of Care on Retention and Time to Treat731
CLO23-045: A Prospective Interventional Study to Assess the Response of Systemic Chemotherapy in Aggressive, Recurrent Giant Cell Tumor574
CLO23-043: Optimal Interval Between Immune Therapy and Targeted Therapy With Sotorasib in Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer504
My Report Card403
EHR-Integrated Patient-Reported Outcomes in Ambulatory Oncology: A Critical Opportunity for Timely and Targeted Palliative Care390
Highlights of the NCCN Oncology Research Program390
HSR24-169: Autonomic Symptoms May Suggest Paraneoplastic Neurological Syndromes in Small Cell Lung Cancer383
HSR24-153: Real-World Clinical Outcomes of First-Line Therapies and Treatment Regimens for BRAF-Mutant Advanced/Metastatic Melanoma: Retrospective Observational Study360
CRE24-049: Extrapulmonary Small Cell Carcinoma of Gallbladder Presenting as Acute Cholecystitis346
HSR24-127: Rectal Cancer Disparities in Age and Overall Survival Among American Indian and Alaska Native Vs Non-Hispanic White Populations345
CLO24-055: Outcomes With Sacituzumab Govitecan in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis344
EPR24-113: The Role of Social Determinants of Health in Gastrointestinal Cancer Outcomes in the United States Context: A Systematic Review317
HSR24-163: Comparative Assessment of Social Determinants of Health in Community and Academic Hospitals for Patients Diagnosed With Hepatocellular Carcinoma299
Intravenous Patient-Controlled Analgesia Versus Oral Opioid to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase II Trial295
CLO22-069: Radiation Induced Lymphopenia (RAILs on Time Saves Nine!) In Carcinoma Esophagus!265
Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors262
HSR22-154: Treatment Patterns Following Osimertinib Discontinuation in Patients With EGFR Mutated Metastatic NSCLC235
NCCN News234
PCL22-186: A Potential Biomarker for Radiosensitivity of Squamous Cell Carcinomas in the Head and Neck176
HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Pha156
Highlights of the NCCN Oncology Research Program152
NCCN News142
Highlights of the NCCN Oncology Research Program140
A New Administration and JNCCN125
CLO22-052: A Tale of Two Schedules: A Study of the Efficacy and Toxicity Outcomes of Extended Durvalumab Dosing in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)122
Oncology Survivorship Care Clinics: Design and Implementation of Survivorship Care Delivery Systems at NCCN Member Institutions122
BPI25-005: Molecular Biomarker Testing Patterns and Turn-Around Time in US Patients With Advanced Non-Small Cell Lung Cancer118
BPI25-019: Empirical Study to Estimate Real World Impact of Delay in EGFR Testing on Healthcare Resource Utilization and Cost Burden Among Early-Stage NSCLC Patients115
BIO25-027: Addressing Early Diagnosis Challenges: Utilizing C the Signs Clinical Decision Support Platform for Pancreatic Cancer Risk Assessment112
Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers111
Evaluation of NCI-Designated Cancer Center and Comprehensive Cancer Center Survivorship-Focused Websites: Information Provided and Accessibility108
HSR24-152: Patient-Reported Outcome (PRO) Data in Oncology NDAs Approved by the FDA (2018–2021): A Review of Criticism and Concerns in Comments From Regulators104
CLO24-060: Organomegalies as a Predictive Indicator of Leukemia Cutis in the Patients With Acute Myeloid Leukemia96
YIA24-005: MAIT Cells are Reduced in Anorectal Mucosal Melanomas Compared to Cutaneous Melanoma GI Metastases96
Statin Use During Concurrent Chemoradiotherapy for Advanced Nasopharyngeal Cancer96
EPR24-099: Clinical and Epidemiological Characterization of the Oncologic Population in a Third Level Hospital in Northeastern Mexico96
EPR25-138: Glioblastoma Multiforme: A SEER STAT Analysis of Epidemiological, Laterality, and Anatomical Prognostic Indicators94
Hemithyroidectomy Versus Total Thyroidectomy for Sporadic Medullary Thyroid Cancer: A Chinese Nationwide Large-Scale Cohort Study87
Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in Matched Cohorts of East Asian and Non-East Asian Men77
HSR25-181: Assessment of Content Validity of the Functional Assessment of Cancer Therapy – Cutaneous T-Cell Lymphoma (FACT-CTCL)75
Advances in the Treatment of Recurrent Ovarian Cancer and Rare Malignant Ovarian Germ Cell Tumors75
HSR25-141: Adolescent and Young Adult Cancer Patients: Our Most Financially Vulnerable Demographic68
EPR25-128: Epidemiology of Olfactory Neuroblastoma: A SEER Stat Review65
Highlights of the NCCN Oncology Research Program65
CLO25-078: Deciphering Risk of Early Biochemical Recurrence in Prostate Cancer Prior to Definitive Therapy65
Empowering Care Teams: Redefining Message Management to Enhance Care Delivery and Alleviate Oncologist Burnout64
Patient-Reported Symptom Complexity and Acute Care Utilization Among Patients With Cancer: A Population-Based Study Using a Novel Symptom Complexity Algorithm and Observational Data64
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.202562
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.202161
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.202259
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology56
QIM24-176: Technology’s Impact on Implementing the NCCN Distress Thermometer in a Community-Based Oncology Clinic55
Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology55
Adult Acute Lymphocytic Leukemia: Strategies for Selection of Consolidation Therapy54
QIM23-140: Health Care Satisfaction Among Cancer Patients Undergoing Radiotherapy: A Tunisian Center Experience52
NCCN News51
Cancer Screening and Surveillance Testing for Older Adult Cancer Survivors49
Impact of the Identification of Nonhuman Genetic Signatures in the Diagnosis and Management of Carcinoma of Unknown Primary48
New Treatment Options for Patients With Bladder Cancer48
Out in the World Again48
CLO22-059: Chemotherapy Timing and Outcomes in Early Breast Cancer47
Optimizing BTK Inhibition in Waldenström Macroglobulinemia37
EPR25-133: Frequency and Pattern of 30-Day Readmissions in Cancer Patients With C.difficile Infection36
CLO22-048: Treatment Outcomes of Metastatic Urothelial Cancer on Immune Checkpoint Inhibition36
CRE25-044: A Case Series of Immunotherapy-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis36
HSR25-151: EPIC Patient Portal Functionality: An Equity Analysis in Vulnerable Cancer Patients35
HSR25-166: Linking COVID-Related Distress and Mental Health Service Utilization Among Allogeneic Hematopoietic Stem Cell Transplant Patients34
HSR25-148: The State of Lung Cancer in Alabama34
Urinary Circular RNA Panels to Detect HBV-Related Hepatocellular Carcinoma: A Multicenter, Large-Scale, Case-Control Study33
HSR25-202: Epidemiology and Outcomes of Ventricular Arrhythmias in Patients With Hypercalcemia of Malignancy: A Population-Based Study33
CLO22-090: Patient Characteristics, Treatment Patterns, and Clinical Outcomes of Patients With Advanced HER2-Low Breast Cancer31
CLO22-051: Influence of Environmental Temperature on Pathological Complete Response and Overall Survival in Breast Cancer: A National Cancer Database Population-Based Study31
21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter TAILORx Clinical Trial29
Long-Term Tumor Stability After First-Line Treatment With Larotrectinib in an Infant With NTRK2 Fusion–Positive High-Grade Glioma29
Worse Survival and Gastrointestinal Toxicity Outcomes Among Patients Receiving Proton Pump Inhibitors During Checkpoint Inhibitor Therapy29
CLO23-059: HDR-ICR Brachytherapy With Solo Anesthesia Administration as a Resource-Effective and Patient-Safe Method in Cancer Cervix28
Hope and Uncertainty in Advanced Cancers27
CLO23-032: Treatment of HER2+ Breast Cancer: A Retrospective of Disease Prognosis With Loss of HER2 Amplification on Residual Disease After Neoadjuvant Treatment in a Community Hospital Setting27
End-of-Life Care Among Patients With Neuroendocrine Tumors: Underutilization of Palliative Care and Racial Disparities26
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study26
Role of Radiation Therapy in Retroperitoneal Sarcoma25
Influence of Food With Different Fat Concentrations on Alectinib Exposure: A Randomized Crossover Pharmacokinetic Trial25
Enhancing Readability of Online Patient-Facing Content: The Role of AI Chatbots in Improving Cancer Information Accessibility25
Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology24
Telehealth Geriatric Assessment and Supportive Care Intervention (GAIN-S) Program: A Randomized Clinical Trial24
NCCN Guidelines® Insights: Bladder Cancer, Version 2.202224
Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related Financial Toxicity24
BIO22-031: Potential Implications in Immunotherapy and Prognostic Outcomes of Non-Small Cell Lung Cancer for Computational Recognition of lncRNA Signature of Tumor-Associated Neutrophils23
Perioperative Management of Anticoagulation and Antithrombotic Therapy23
Machine Learning–Based Early Warning Systems for Acute Care Utilization During Systemic Therapy for Cancer23
Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer: A Potential Strategy for Systemic Therapy Deferral23
Updates to the Management of Patients With Relapsed or Refractory Indolent Follicular and Marginal Zone Lymphomas23
QIM22-203: Randomized Trial of Implementing a Clinical Decision Support Tool for Automatic Selection of Payor-Mandated Biosimilar at Time of Prescribing23
CLO22-086: A Phase 2, Multi-Arm Study of Anti-CD47 Antibody Magrolimab in Combination With Docetaxel in Patients With Locally Advanced or Metastatic Solid Tumors23
Management of Patients With Resectable and Metastatic Non–Small Cell Lung Cancer22
CGE23-071: Real World Data on the Implementation of a Hereditary Hematological Myeloid Malignancy Workflow: Experience of a Single Academic Medical Center22
NCCN News22
CLO22-053: Risk Factors of Paclitaxel Induced Peripheral Neuropathy in Early Breast Cancer Patient in Relation to Mean Changes of Neuropathy Growth Factors and Serum Malondialdehyde22
NCCN News21
Mitigating the Risk of Aberrant Use of Opioids in Patients With Cancer Pain21
EPR24-101: Characteristics of Individuals With Early-Onset GI Cancers in the Southeastern US20
The Value and Process of Inclusion: Using Sensitive, Respectful, and Inclusive Language and Images in NCCN Content19
The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL19
HSR24-166: Implementation of an Integrated Supportive Care Medicine Consultation Service Within a Gastrointestinal Cancer Clinic: Timeliness of Referrals and Patient Access19
BIO25-024: Real-Time Clinical Trial Data Library in Non-Small Cell Lung (NSCLC), Prostate (PC), and Breast Cancer (BC) to Support Informed Treatment Decisions: Now a Reality With a Fine-Tuned Large La19
NCCN Policy Summit: Cancer Across Geography19
Integrating Immune Therapies for the Treatment of Multiple Myeloma19
Molecular Profiling of Endometrial Cancer From TCGA to Clinical Practice19
Promising Practices to Reduce the Impact of Drug Shortages on Cancer Care19
HSR25-153: Patient Preferences and Willingness to Accept Trade-Offs for a Favorable Treatment Response Among Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer18
HSR24-171: Utilizing Diverse Enrollment to Validate the DELFI Fragmentome Test for Advancing Lung Cancer Screening18
HSR25-172: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Infectious Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Ma18
QIM25-228: Utilizing Patient and Provider Perspectives in Psycho-Oncology Program Development and Quality Improvement18
Changes for JNCCN in 202518
HSR25-204: Clinical Characteristics and Prognosis Associated With Low PSA in Patients With De Novo Metastatic Hormone Sensitive Prostate Cancer17
HSR25-190: Clinical Experience With Immunotherapy in Advanced Solid Tumors – Real World Data From India17
QIM25-230: Enhancing Communication Through Interprofessional Goal Concordant Care Training17
BIO25-026: Innovating a Digital Patient Navigation Platform (DPNP) to Help Patients With Melanoma Access Multidisciplinary Cutaneous Oncology Care16
CLO25-102: Survival Outcomes in Breast Cancer Patients With Diseased Axillary Lymph Nodes: The Role of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy.16
YIA25-001: Molecular Residual Disease (MRD) Guided Adjuvant Therapy In Renal Cell Carcinoma (RCC) - The MRD GATE RCC Study16
Key Performance Indicators and Metrics for the Implementation of an Oral Chemotherapy Adherence Program16
Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non–Small Cell Lung Cancer Using a Real-World Database16
Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy15
First-Line PD-1 Blockade Combined With Chemotherapy for Stage IV Penile Squamous Cell Carcinoma: A Multicenter Retrospective Study15
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.202215
Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology15
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology15
Compliance With NCCN Guidelines for Evaluation and Treatment of Anemia Among Patients With Solid Tumors15
Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology15
Disparate Use of Chemoradiation in Elderly Patients With Localized Anal Cancer15
NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.202215
Erratum14
Addressing Racial Inequity in Cancer Care: Self-Awareness Among Oncology Professionals14
Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology14
EPR22-106: Decelerating Decline and Urban-Rural Differences for Gastrointestinal Cancer Mortality in the United States, 1999-201914
CLO22-066: Toxicity of a Modified PEG-Asparaginase Based SMILE Regimen is Comparable to L-Asparaginase Based SMILE in a non-Asian Population14
Unusual Adverse Events in a Patient With BRAF-Mutated Non–Small Cell Lung Cancer Treated With BRAF/MEK Inhibition13
EPR23-080: Oral Cancer Screening Among the Rural Indians—A Community Based Prospective Study13
High-Risk Prevention Programs: Identifying Services for High-Risk Patients13
CLO23-068: Effectiveness and Toxicity of Cetuximab With Concurrent Radiotherapy in Locally Advanced Cutaneous Squamous Cell Skin Cancer: A Case Series13
BPI23-016: Interventional Pain Management in Outpatient Setting for Cancer Patients: A Review of Literature13
NCCN News13
HSR24-126: “Share the Fear”: Communication Concerns of Parents With Cancer With Dependent Children for Their Co-Parent: A Qualitative Study13
CLO23-039: Safety Profile of Sonic Hedgehog Inhibitors in Basal Cell Carcinoma: A Systematic Review13
HSR23-121: Assessment of Sustained MRD Negativity and Reversion in Real-World Multiple Myeloma Patients Using NGS (clonoSEQ Assay)13
BPI22-010: Applying FRAME to Code Modifications to a Community-Based Educational Intervention and Lung Cancer Screening Protocols Amidst the Covid-19 Pandemic13
Abstracts From the NCCN 2023 Annual Conference12
CRE25-043: Treatment of HER2-Positive Breast Cancer With Leptomeningeal Metastases With Intrathecal Trastuzumab12
CRE24-038: Neuroendocrine Tumor of the Gallbladder: A Case Report and Literature Review.12
HSR25-203: Cost-Effectiveness Evaluation of Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments Among Medicare Patients With Chronic Lymphocytic Leukemia (CLL) in First-Line (1L) and Relapsed/Refractor12
BIO22-028: Identification of Gene Expression Signature Associated With Overall Survival in Patients With Non-Small Cell Lung Cancer12
Optimizing First-Line Therapy for Advanced-Stage Classic Hodgkin Lymphoma12
BPI24-010: Temporary Toilet Lids Minimize Contamination of Bathroom Surfaces With Hazardous Drugs12
Highlights of the NCCN Oncology Research Program12
CRE25-041: Pneumocephalus in the Setting of Endometrial Adenocarcinoma: A Case Report12
CLO25-080: Outcomes of Extreme Low PD-L1 Expression in Advanced Non-Small Cell Lung Cancer: Implications for Treatment Approaches12
HSR24-150: Real-World Treatment Patterns of Selumetinib Among Patients With Neurofibromatosis Type I and Plexiform Neurofibroma in the United States11
EPR22-118: Incidence of Herpes Zoster in Immunocompromised Individuals and Zoster Vaccination as an Effective Preventative Strategy11
NCCN Guidelines for Central Nervous System Cancers: Updates in the Treatment of Adult Patients With Glioma11
HSR24-148: Outcome of Positron Emission Tomography–Computed Tomography Staging in Breast Cancer Patients Having Neo-Adjuvant Systemic Therapy11
Letter to the Editor: Differentiating Between Intentional Versus Unintentional Weight Loss11
Authors’ Reply to the Letter to the Editor by Liu and Kesselheim11
Reaching Populations to Address Disparities in Cancer Care Delivery: Results From a Six-Site Initiative11
HSR24-173: Reaching Unmet Needs of Lung Cancer Patients Through Hope Totes and Educational Meetings11
Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults11
Treatment Updates for Small Cell Lung Cancer11
Aligning With the National Cancer Plan11
Revisiting the Association of ECOG Performance Status With Clinical Outcomes in Diverse Patients With Cancer10
Importance of Family History of Colorectal Carcinoma In Situ Versus Invasive Colorectal Cancer: A Nationwide Cohort Study10
Preoperative and Postoperative Approaches to Gastroesophageal Cancer: What is All the Fuss About10
Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment10
Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model10
Comparative Effects of Hospital Volume and Safety-Net Status on Treatment Use and Outcome Measures in Hepatocellular Carcinoma10
Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair–Deficient Colorectal Cancer10
Updates to Management of Multiple Myeloma10
Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study10
Current and Emerging Biomarkers: Impact on Risk Stratification for Neuroblastoma10
Navigating the Challenges: Effective Management of Toxicities in CAR T-Cell Therapies10
EPR22-113: Awareness, Utilization, and NCCN Guideline-Adherence to Breast Cancer Risk Management Behavior Among a Community-Based Sample of High-Risk Women10
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.20229
HSR23-113: Patient and Provider Perspectives on How COVID-19 Impacted Melanoma Care Delivery9
BPI22-023: Strategies to Prevent Unplanned Emergency Department (ED) Utilization in the COVID-19 Era9
QIM23-133: Aligning NCCN Criteria With Testing Workflows Using a Novel Database Application (Criterion™)9
CLO23-026: Hydrogel Slope and Optimization of Prostate-Rectal Hydrogel Placement9
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma9
HSR23-112: Disease Burden and Treatment Patterns in Patients Diagnosed With HER2- Metastatic Gastric/Gastroesophageal Junction Cancer (mG/GEJC)9
CLO23-040: Electrocardiographic Findings in Cancer Patients Receiving Chemotherapy From the Colombian Coffee Triangle Region9
Associations Among Optimal Lung Cancer Treatment, Clinical Outcomes, and Health Care Utilization in Patients Who Underwent Comprehensive Genomic Profiling9
Highlights of the NCCN Oncology Research Program9
BPI22-016: Leveraging Best Practices in Tobacco Cessation for Cancer Patients: The Fox Chase Cancer Center (FCCC) Case Study8
QIM25-227: Evaluating Dosimetric Differences in Head and Neck Cancer Treatment: A RapidArc Approach With Flattening Filter-Free vs. Filtered Beams8
NCCN News8
Symptom Burden and Survivorship Care for Patients With Prostate Cancer on Androgen Deprivation Therapy8
T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy8
HSR25-144: Clinical Outcomes for Leukemia Patients Following Hematopoietic Stem Cell Transplant: An Analysis of the National Inpatient Sample8
CLO25-083: Immune-Related Adverse Events in Women With Early and Advanced Triple-Negative Breast Cancer Treated With Pembrolizumab: A Multi-Center Analysis8
EPR24-117: A Comprehensive Examination of Disparities in Metastatic Breast Cancer Incidence: Race, Income and Geography8
QIM25-223: Acceptability, Facilitators, and Barriers to the Implementation of Screening and Brief Intervention for Alcohol Counseling in the Oncology Setting8
QIM24-178: Managing Pharmaceutical Costs in the Oncology Care Model8
EPR25-137: Epidemiology and Prognostication of Malignant Glomus Tumor8
HSR25-175: Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Venous Thromboembolism (VTE) and Immune-Related Adverse Events (iRAEs) in Patients With Primary Advanced or8
Optimizing Electronic Secure Messaging to Mitigate Oncologist Burnout8
BPI24-013: Microwave Ablation Versus Resection Versus Stereotactic Body Radiation Therapy of Stage IA Non–Small Cell Lung Cancer in US Veterans8
Cardiovascular Adverse Events and Associated Costs of CDK4/6 Inhibitors in Patients With Breast Cancer8
Failure Doesn’t Feel Good!7
BPI24-026: Utilization of ExoDx Prostate Test for Prostate Cancer Risk Stratification in the African American Population7
Association Between Cancer Center Accreditation and Compliance With Price Disclosure of Common Oncologic Surgical Procedures7
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology7
Mitigating Inequities? Or Compromising Patient Privacy and Safety?7
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma7
CRE24-053: Brown Fat Adipose Tissue (BAT) Activation Mimicking Lymphoma-Associated Lymphadenopathy7
Letter to the Editor: The Role of Skin Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity7
HSR22-158: Managing Diabetes Mellitus During Cancer Treatment: The Missing Link to Primary Care7
I Cannot Afford This!7
CLO24-058: Evaluation of Aromatherapy With Lavender Oil During the Perioperative Period of Benign Prostate Hyperplasia: A Randomized Placebo Controlled Clinical Observation7
Letter to the Editor: Methodological Limitations in Breast Cancer Survivorship Research: Beyond Linear Regression7
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer7
Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability–High Gastric Cancer: A Case Series7
Incident Cancer Detection During Multiple Waves of COVID-19: The Tsunami After the Earthquake7
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.20247
CRE24-042: Microgranular Acute Promyelocytic Leukemia Presenting as Recurrent Stroke and Isolated Neutropenia7
HSR22-173: Treatment Patterns, Healthcare Resource Use and Costs Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer Following Discontinuation of Osimertinib and Platinum-Based Chemotherapy7
HSR22-124: Real-World Outcomes Among Patients With Stage IV Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer Treated With EGFR Tyrosine Kinase Inhibitors Versus Immunotherapy7
NCCN Guidelines® Updates: T-Cell Lymphomas7
NCCN News7
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.20247
Updates in the Management of Biliary Tract Cancers7
Referral, Uptake, and Outcome of Genetic Counseling and Testing in Patients With Early-Onset Colorectal Cancer7
CLO25-070: Effects and Mechanisms of CD16+/-NK Cells on Ovarian Malignant Tumor Cells Platinum-Based Drug Responsiveness in Tumor Microenvironment7
EPR23-082: Patient Awareness of Elevated Breast Cancer Risk After Routine Screening Mammogram and Risk Notification7
HSR22-155: Management of Close/Positive Margins in cSCCHN7
Association of HOXB13 G84E With Prostate Cancer Among 592,158 Men6
Integrating Diversity, Equity, and Inclusion Approaches Into Treatment of Commercial Tobacco Use for Optimal Cancer Care Delivery6
Erratum to: NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.20226
QIM23-142: Evaluation of a Standardized Approach to Hypersensitivity/Infusion Reaction Management in a Large Ambulatory Oncology Center6
CLO22-071: Does Tumor Site Have Independent Prognostic Ability in Breast Cancer? A Deep Learning Approach6
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology6
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology6
The Prognostic Role of HPV or p16INK4a Status in Penile Squamous Cell Carcinoma: A Meta-Analysis6
Letter to the Editor: Revisiting a “Revised Perspective on the American Joint Committee on Cancer’s Staging System for Medullary Thyroid Cancer”6
CLO22-091: Malignancy or Not? Role of 18F-FDG PET/CT in Solving the Diagnostic Dilemma in Multiple Myeloma Misdiagnosed as Rheumatoid Arthritis: Pictorial Series6
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology6
HSR25-168: Survival Analysis for Early Onset and Very Early Onset Colon Cancer Using National Cancer Database (NCDB) 2004-20216
Local Recurrence and Survival in Patients With Melanoma >2 mm in Thickness at Difficult Sites Treated With 1-cm Versus 2-cm Margins6
Rurality Status and Cardiovascular Events/Survival in Older Men With Prostate Cancer6
Authors’ Reply to the Letter to the Editor by Foote et al: Revisiting a “Revised Perspective on the American Joint Committee on Cancer’s Staging System for Medullary Thyroid Cancer”6
Advancing Health Equity in Cancer-Related Distress: Lessons Learned From the COVID-19 Pandemic on Leveraging Digital Tools and Future Directions6
CLO22-079: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer6
0.14812612533569